查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1880424

高血钾治疗市场预测至2032年：按药物类型、给药途径、通路、适应症、最终用户和地区分類的全球分析

Hyperkalemia Drugs Market Forecasts to 2032 - Global Analysis By Drug Type, Route of Administration, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的一项研究，预计到 2025 年，全球高血钾治疗市场价值将达到 14.2 亿美元，到 2032 年将达到 39.7 亿美元，在预测期内的复合年增长率为 15.8%。

高血钾药物旨在降低异常高的血钾水平，过高的血钾会干扰正常的心臟活动并带来严重的健康风险。这些治疗方法透过以下方式发挥作用：将钾离子重新带回细胞内，促进排放透过尿液和消化器官系统排出体外，或在肠道内与钾离子结合以限制其吸收。常用的治疗方法包括利尿剂、葡萄糖胰岛素、磺酸盐磺酸钠和新型钾结合剂。这些药物在恢復安全的血钾平衡和保护患者免受危险的心臟併发症发挥着至关重要的作用。

RAAS抑制剂的使用日益增多

由于这些药物会升高血钾水平，临床医生越来越依赖钾粘合剂来维持电解质平衡。治疗监测工具和电子处方平台的进步也促进了钾结合剂的更广泛应用。新的临床指引建议长期使用肾素-血管张力素-醛固酮系统（RAAS）抑制剂，间接凸显了有效管理高血钾的必要性。新兴的数位化依从性技术使得高血钾药物与RAAS抑制剂合併用药更加安全。随着精准医疗的进步，针对个人风险状况量身定制的联合治疗策略在临床实践中日益普及。

患者依从性挑战

许多钾粘合剂需要特定的给药方案，这可能导致长期依从性较低。儘管出现了每日一次给药和易于吞嚥的粉剂等新剂型，但维持患者的持续用药仍然是一项挑战。数位健康工具，例如提醒应用程式和自动追踪系统，正在兴起以解决依从性问题。然而，即使有了技术支持，生活方式的限制和胃肠道副作用也会阻碍规律用药。此外，某些地区病患教育不足也减缓了先进高血钾治疗方法的普及。

整合数位健康和​​个人化医疗

远端监测平台能够持续追踪血钾水平，使临床医师能够快速调整治疗方案。基于人工智慧的风险评估工具能够更准确地预测高血钾的发生，从而支持预防性治疗策略。製药公司正与数位医疗Start-Ups合作，开发整合式医疗服务路径。包括药物基因组学分析在内的个人化医疗策略，正在改善药物选择和治疗反应。这些技术和治疗方法的融合，为市场快速创新和提高患者参与度奠定了基础。

价格压力与报销政策变化

卫生部门正日益关注慢性钾结合剂治疗的成本效益。学名药竞争加剧，对价格较高的品牌药带来压力。与真实世界疗效挂钩的新型报销模式要求企业证明其产品具有持续的临床疗效。在关键市场，以技术主导的卫生经济评估正成为支付方决策的核心。如果没有适应性定价策略，製造商在对价格敏感的地区可能会面临进入限制。

新冠疫情的感染疾病：

供应链中断影响了多个地区的药品供应。然而，新冠疫情加速了远端医疗的普及，并改善了弱势患者的远端医疗管理。电子处方笺和虚拟咨询增强了封锁期间的医疗服务连续性。监管机构推出了临时性灵活措施，加快了更新配方和给药系统的核准。疫情后，医疗系统正优先发展以数位化为先导的照护模式和针对慢性病（包括高血钾）的去中心化治疗管道。

预计在预测期内，聚苯乙烯磺酸盐（SPS）细分市场将占据最大的市场份额。

由于聚苯乙烯磺酸盐（SPS）具有悠久的临床应用历史和良好的成本效益，预计在预测期内，SPS仍将占据最大的市场份额。其在医院和零售药局的广泛供应持续支撑着强劲的需求。近期研发的改进提升了粉末製剂的性能，简化了给药方法，进一步扩大了其应用范围。 SPS是医疗专业人员熟悉的药物，因此常用于紧急情况。儘管出现了新的替代药物，但由于其价格实惠，SPS在发展中国家仍然是首选。

预计在预测期内，居家医疗环境领域将呈现最高的复合年增长率。

预计在预测期内，居家医疗保健领域将实现最高成长率，这主要得益于慢性病管理在医院外的兴起。远端监测设备的广泛应用使高血钾的居家管理更加安全。新型携带式钾结合剂和易于服用的製剂也提高了居家照护的接受度。远端医疗的整合使医生无需面对面会诊即可调整剂量。成本节约和便利性促使患者更倾向于选择居家照护而非传统的临床照护。

占比最大的地区：

由于糖尿病、肾臟病和心血管疾病患者人数不断增加，预计亚太地区将在预测期内占据最大的市场份额。医疗基础设施的快速发展正在改善高血钾先进治疗的可近性。中国、印度和日本政府正在推动国内药品生产和数位医疗整合。行动医疗技术的应用正在改善医疗服务的连续性和钾监测的准确性。对基于人工智慧的诊断平台的投资不断增长，正在加速电解质异常的早期检测。

复合年增长率最高的地区：

在预测期内，由于强劲的技术进步和高端高血钾治疗方法的早期应用，北美预计将实现最高的复合年增长率。该地区强大的研发生态系统支持钾结合剂和数位治疗工具的持续创新。医疗服务提供者正在整合以人工智慧为基础的监测系统，以优化慢性病管理。有利的报销机制使患者更容易获得新型高效的疗法。远距远端医疗和连网设备的日益普及正在促进高血钾的主动管理。

免费客製化服务：

购买此报告的客户可以选择以下免费自订选项之一：

  • 公司概况
    • 对其他市场公司（最多 3 家公司）进行全面分析
    • 主要企业SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户要求，提供主要国家的市场估算、预测和复合年增长率（註：可行性需确认）。
  • 竞争基准化分析
    • 根据主要企业的产品系列、地理覆盖范围和策略联盟基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 原始研究资料
    • 次级研究资讯来源
    • 先决条件

第三章 市场趋势分析

  • 介绍
  • 司机
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球高血钾治疗市场（依药物类型划分）

  • 介绍
  • 磺酸盐磺酸钠（SPS）
  • 帕蒂·罗梅尔
  • 环硅酸锆钠
  • 磺酸盐磺酸钙
  • 其他药物类型

6. 全球高血钾治疗市场（依给药途径划分）

  • 介绍
  • 口服
  • 静脉

7. 全球高血钾治疗市场（依通路）

  • 介绍
  • 医院药房
  • 零售药房
  • 网路药房

8. 全球高血钾治疗市场（依适应症划分）

  • 介绍
  • 急性高血钾
  • 慢性高血钾症
  • 其他迹象

9. 全球高血钾治疗市场（以最终用户划分）

  • 介绍
  • 医院
  • 诊所
  • 门诊手术中心
  • 居家照护机构
  • 其他最终用户

第十章 全球高血钾治疗市场（按地区划分）

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与併购
  • 新产品上市
  • 业务拓展
  • 其他关键策略

第十二章 企业概况

  • AstraZeneca
  • CMP Pharma
  • Vifor Pharma
  • Keryx Biopharmaceuticals
  • Sanofi
  • OPKO Health
  • Perrigo Company plc
  • Viatris
  • Ardelyx
  • Fresenius Kabi
  • Baxter International
  • scPharmaceuticals
  • Pfizer
  • Camber Pharmaceuticals
  • Teva Pharmaceutical Industries
Product Code: SMRC32556

According to Stratistics MRC, the Global Hyperkalemia Drugs Market is accounted for $1.42 billion in 2025 and is expected to reach $3.97 billion by 2032 growing at a CAGR of 15.8% during the forecast period. Hyperkalemia drugs are medications designed to reduce abnormally high potassium levels, which can impair normal heart activity and pose severe health risks. These therapies act by moving potassium back into cells, promoting its removal through urine or the digestive system, or binding it within the gut to limit absorption. Frequently used treatments include diuretics, glucose-assisted insulin, sodium polystyrene sulfonate, and modern potassium-binding formulations. Such drugs play a critical role in restoring safe potassium balance and protecting patients from dangerous cardiac complications.

Market Dynamics:

Driver:

Increased use of RAAS inhibitors

As these drugs elevate potassium levels, clinicians increasingly rely on potassium binders to maintain electrolyte balance. Advancements in therapeutic monitoring tools and e-prescription platforms are supporting wider prescribing confidence. New clinical guidelines promoting long-term RAAS inhibitor use are indirectly amplifying the need for effective hyperkalemia management. Emerging digital adherence technologies are ensuring safer co-administration of hyperkalemia drugs with RAAS inhibitors. With precision medicine growing, combination strategies tailored to individual risk profiles are becoming more common in clinical practice.

Restraint:

Challenges with patient compliance

Many potassium binders require specific dosing schedules, which can reduce long-term compliance. Although new formulations like once-daily or palatable powders are being introduced, consistent patient engagement remains difficult. Digital health tools such as reminder apps and automated follow-up systems are emerging to address adherence gaps. Even with technological support, lifestyle restrictions and gastrointestinal side effects still deter regular use. Limited patient education in some regions also slows the adoption of advanced hyperkalemia therapies.

Opportunity:

Integration of digital health and personalized medicine

Remote monitoring platforms are enabling continuous potassium level tracking, helping clinicians make quicker adjustments to therapy. AI-based risk assessment tools are predicting hyperkalemia episodes more accurately, supporting preventive treatment approaches. Pharmaceutical companies are collaborating with digital health startups to develop integrated care pathways. Personalized medicine strategies, including pharmacogenomic profiling, are improving drug selection and treatment response. This convergence of technology and therapeutics is positioning the market for rapid innovation and expanded patient engagement.

Threat:

Pricing pressure and reimbursement changes

Health authorities are increasingly reviewing the cost-effectiveness of chronic potassium binder therapy. Generic competition is rising, intensifying the pressure on premium-priced branded products. New reimbursement models tied to real-world outcomes are challenging companies to demonstrate consistent clinical benefits. Technology-driven health economic evaluations are becoming central to payer decisions across major markets. Without adaptive pricing strategies, manufacturers may face limited access in cost-sensitive regions.

Covid-19 Impact:

Supply chain interruptions affected drug availability in several regions. However, COVID-19 accelerated telehealth adoption, improving remote treatment oversight for vulnerable patients. Digital prescribing and virtual consultations enhanced continuity of care during lockdowns. Regulatory agencies introduced temporary flexibilities that allowed faster approval of updated formulations and delivery systems. Post-pandemic, health systems are prioritizing digital-first care models and decentralized treatment channels for chronic conditions including hyperkalemia.

The sodium polystyrene sulfonate (SPS) segment is expected to be the largest during the forecast period

The sodium polystyrene sulfonate (SPS) segment is expected to account for the largest market share during the forecast period, due to its long-standing clinical use and cost-effectiveness. Its wide availability across hospitals and retail pharmacies continues to support strong demand. Recent developments in improved powder formulations and easier administration methods are reinforcing its adoption. SPS is frequently utilized in emergency settings due to its familiarity among practitioners. Despite emerging alternatives, its affordability makes it the preferred choice in developing markets.

The home care settings segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the home care settings segment is predicted to witness the highest growth rate, due to increasingly manage chronic disorders outside hospital environments. Growing adoption of remote monitoring devices is enabling safer home-based hyperkalemia management. New portable potassium binders and easy-to-consume formulations are boosting acceptance in home-based care. Telehealth integration is allowing physicians to adjust dosing without requiring in-person visits. Cost savings and convenience are driving patient preference toward home care over traditional clinical settings.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to its expanding population of patients with diabetes, kidney disorders, and cardiovascular conditions. Rapid healthcare infrastructure development is enhancing access to advanced hyperkalemia treatments. Governments across China, India, and Japan are promoting domestic drug manufacturing and digital health integration. Adoption of mobile health technologies is improving treatment continuity and potassium monitoring. Growing investments in AI-based diagnostic platforms are accelerating early detection of electrolyte disorders.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, driven by strong technological advancements and early adoption of premium hyperkalemia therapies. The region's robust R&D ecosystem supports continuous innovation in potassium binders and digital therapeutic tools. Healthcare providers are integrating AI-based monitoring systems to optimize chronic condition management. Favourable reimbursement structures are accelerating patient access to newer, high-efficacy treatments. Increasing use of telemedicine and connected devices is enhancing proactive hyperkalemia control.

Key players in the market

Some of the key players in Hyperkalemia Drugs Market include AstraZeneca, CMP Pharma, Vifor Pharma, Keryx Biopharma, Sanofi, OPKO Health, Perrigo Co, Viatris, Ardelyx, Fresenius, Baxter International, scPharmaceuticals, Pfizer, Camber Pharma, and Teva Pharma.

Key Developments:

In July 2025, Sanofi announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a promising pipeline, and the expertise of a company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases.

In June 2022, CMP Pharma announced that Norliqva(R) (Amlodipine) Oral Solution, 1 mg/mL, the first and only FDA-approved oral liquid solution of the besylate salt of amlodipine, a long-acting calcium channel blocker, is now available. Norliqva was approved by the FDA on February 24, 2022 and is now available through normal retail distribution.

Drug Types Covered:

  • Sodium Polystyrene Sulfonate (SPS)
  • Patiromer
  • Sodium Zirconium Cyclosilicate
  • Calcium Polystyrene Sulfonate
  • Other Drug Types

Route of Administrations Covered:

  • Oral
  • Intravenous

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Applications Covered:

  • Acute Hyperkalemia
  • Chronic Hyperkalemia
  • Other Applications

End Users Covered:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Home Care Settings
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Hyperkalemia Drugs Market, By Drug Type

  • 5.1 Introduction
  • 5.2 Sodium Polystyrene Sulfonate (SPS)
  • 5.3 Patiromer
  • 5.4 Sodium Zirconium Cyclosilicate
  • 5.5 Calcium Polystyrene Sulfonate
  • 5.6 Other Drug Types

6 Global Hyperkalemia Drugs Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Oral
  • 6.3 Intravenous

7 Global Hyperkalemia Drugs Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital Pharmacies
  • 7.3 Retail Pharmacies
  • 7.4 Online Pharmacies

8 Global Hyperkalemia Drugs Market, By Application

  • 8.1 Introduction
  • 8.2 Acute Hyperkalemia
  • 8.3 Chronic Hyperkalemia
  • 8.4 Other Applications

9 Global Hyperkalemia Drugs Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Clinics
  • 9.4 Ambulatory Surgical Centers
  • 9.5 Home Care Settings
  • 9.6 Other End Users

10 Global Hyperkalemia Drugs Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 AstraZeneca
  • 12.2 CMP Pharma
  • 12.3 Vifor Pharma
  • 12.4 Keryx Biopharmaceuticals
  • 12.5 Sanofi
  • 12.6 OPKO Health
  • 12.7 Perrigo Company plc
  • 12.8 Viatris
  • 12.9 Ardelyx
  • 12.10 Fresenius Kabi
  • 12.11 Baxter International
  • 12.12 scPharmaceuticals
  • 12.13 Pfizer
  • 12.14 Camber Pharmaceuticals
  • 12.15 Teva Pharmaceutical Industries

List of Tables

  • Table 1 Global Hyperkalemia Drugs Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Hyperkalemia Drugs Market Outlook, By Drug Type (2024-2032) ($MN)
  • Table 3 Global Hyperkalemia Drugs Market Outlook, By Sodium Polystyrene Sulfonate (SPS) (2024-2032) ($MN)
  • Table 4 Global Hyperkalemia Drugs Market Outlook, By Patiromer (2024-2032) ($MN)
  • Table 5 Global Hyperkalemia Drugs Market Outlook, By Sodium Zirconium Cyclosilicate (2024-2032) ($MN)
  • Table 6 Global Hyperkalemia Drugs Market Outlook, By Calcium Polystyrene Sulfonate (2024-2032) ($MN)
  • Table 7 Global Hyperkalemia Drugs Market Outlook, By Other Drug Types (2024-2032) ($MN)
  • Table 8 Global Hyperkalemia Drugs Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 9 Global Hyperkalemia Drugs Market Outlook, By Oral (2024-2032) ($MN)
  • Table 10 Global Hyperkalemia Drugs Market Outlook, By Intravenous (2024-2032) ($MN)
  • Table 11 Global Hyperkalemia Drugs Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 12 Global Hyperkalemia Drugs Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 13 Global Hyperkalemia Drugs Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 14 Global Hyperkalemia Drugs Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 15 Global Hyperkalemia Drugs Market Outlook, By Application (2024-2032) ($MN)
  • Table 16 Global Hyperkalemia Drugs Market Outlook, By Acute Hyperkalemia (2024-2032) ($MN)
  • Table 17 Global Hyperkalemia Drugs Market Outlook, By Chronic Hyperkalemia (2024-2032) ($MN)
  • Table 18 Global Hyperkalemia Drugs Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 19 Global Hyperkalemia Drugs Market Outlook, By End User (2024-2032) ($MN)
  • Table 20 Global Hyperkalemia Drugs Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 21 Global Hyperkalemia Drugs Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 22 Global Hyperkalemia Drugs Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 23 Global Hyperkalemia Drugs Market Outlook, By Home Care Settings (2024-2032) ($MN)
  • Table 24 Global Hyperkalemia Drugs Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.